Product News

FDA has approved Sanofi-Aventis's Nasacort AQ for use in children aged two to five years old. The indication is for nasal symptoms associated with perennial allergic rhinitis.

 The FDA will conduct trials to establish the safety of Teva's generic version of GlaxoSmithKline's Wellbutrin XL. The review was prompted by patients complaining of side effects after switching from the brand to the generic.

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.